Crotalidae polyvalent immune fab (ovine) - Biologic Drug Details

Summary for crotalidae polyvalent immune fab (ovine)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for crotalidae polyvalent immune fab (ovine)

Ingredient-type	Antivenins
Mechanism of Action	Venom Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Antivenin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for crotalidae polyvalent immune fab (ovine) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for crotalidae polyvalent immune fab (ovine) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for crotalidae polyvalent immune fab (ovine) Derived from Patent Text Search

No patents found based on company disclosures

Crotalidae polyvalent immune fab (ovine) Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Crotalidae Polyvalent Immune Fab (Ovine)?

Crotalidae polyvalent immune fab (ovine) is a biologic antivenom developed to treat envenomations from crotaline snakes—pit vipers such as rattlesnakes, copperheads, and cottonmouths. The drug is marketed primarily by BTG International (a division of Boston Scientific) and has an established presence in the US, with limited penetration outside North America.

Market Size and Growth Drivers

The global snakebite envenomation market, estimated at $150 million in 2022, is driven by several factors:

• Incidence of Snakebites: The World Health Organization (WHO) estimates 81,000–138,000 deaths annually, with many more survivors suffering from permanent disability. The US reports approximately 7,000–8,000 cases annually [1].

• Geographical Reach: North America accounts for 50% of the global snakebite incidents; Africa and Asia show higher incidence rates but have limited access to advanced antivenoms.

• Product Adoption: As the standard of care, crotalidae immune fab is deliverable in emergency settings; its use is restricted by availability and awareness.

• Regulatory Landscape: FDA approval in 2000 facilitated market entry in the US; however, production remains constrained by the limited number of manufacturers.

Supply and Demand Challenges

• Supply Constraints: Manufacturing relies on immunized ovine plasma, with production affected by animal health and supply chain issues.

• Demand Uncertainty: Fluctuates with snakebite incidence rates, healthcare infrastructure, and physician awareness.

• Pricing and Reimbursement: The drug retails around $6,000–$8,000 per vial; treatment typically requires 4–6 vials, making total costs $24,000–$48,000. Reimbursement networks and variability affect overall adoption.

Competitive Landscape

• Other Antivenoms: Limited competition in the US; Indian and South American markets use region-specific antivenoms, which differ in formulation and efficacy.

• Emerging Alternatives: Research into recombinant antivenoms and monoclonal antibodies is ongoing but not commercially available.

Market Trends

• Increasing Awareness and Reporting: Public health organizations promote faster diagnosis and treatment.

• Advancements in Production: Biotechnological improvements aim to increase yield and reduce costs.

• Potential for Regional Expansion: Partnership with emerging markets could expand access but faces regulatory and logistical barriers.

What Is the Financial Trajectory for Crotalidae Polyvalent Immune Fab (Ovine)?

Revenue Trends

Since its FDA approval, annual US sales have hovered in the $50–$70 million range, with modest growth observed over the past decade owing mainly to increased snakebite awareness and healthcare provider adoption. The global market remains limited, with modest exports or licensing agreements.

Cost Structure

• Manufacturing: Involves immunization of sheep, plasma collection, purification, and formulation. High capital expenditure exists for production facilities.

• Research & Development: Ongoing costs include process improvement, scale-up efforts, and safety testing. R&D spends are less aggressive given the product's approved status, but innovation is limited.

• Regulatory & Compliance: Costs related to maintaining approvals, quality control, and post-marketing surveillance.

Profitability Outlook

• Margins: Retail prices allow for gross margins exceeding 50%. However, high production costs and limited volume constrain profitability potential without price adjustments or cost reductions.

• Growth Potential: Modest, due to low disease prevalence in advanced economies and manufacturing capacity constraints.

Future Revenue Opportunities

• Expansion into Emergency Medicine: Increased training and protocol updates could marginally boost adoption.

• Regional Market Penetration: Emerging markets with high snakebite incidence could be targeted via licensing, potentially increasing global revenues.

• Product Innovation: Development of next-generation antivenoms might disrupt current revenue streams, but this remains speculative and requires significant R&D investment.

Risks

• Manufacturing Limitations: Capacity constraints could hinder supply to meet rising demand.

• Pricing Pressures: Payer negotiations and political initiatives for price control could reduce margins.

• Regulatory Changes: Revisions in approval standards may necessitate additional clinical trials, increasing costs.

Key Takeaways

Crotalidae polyvalent immune fab (ovine) operates in a niche market with limited yet steady demand. Its commercial success hinges on manufacturing capacity, healthcare provider awareness, and regional expanding access. While current sales are stable, growth prospects are modest without significant efforts to broaden geographic reach or innovate the product.

FAQs

1. What factors influence the global adoption of crotalidae immune fab?
Demand correlates with snakebite incidence rates, healthcare infrastructure, regulatory approval, and physician familiarity. Supply constraints and high treatment costs also impact adoption.

2. Are there competing products in the same market?
In the US, no significant direct competitors exist; global alternatives include region-specific antivenoms with varying efficacy and safety profiles.

3. How could emerging biotechnologies impact the market?
Recombinant monoclonal antivenoms could reduce production costs and improve safety, presenting future competition but are not yet commercially available.

4. What regulatory challenges face expansion into emerging markets?
Different regional standards, the need for local clinical data, and logistical issues in plasma collection and manufacturing pose barriers.

5. What are potential avenues for revenue growth?
Expanding regional licensing, improving manufacturing capacity, and investing in product innovation offer opportunities, though each faces significant hurdles.

---

Sources

[1] WHO. Snakebite Envenoming, Fact Sheet. 2022.